Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Intellia Therapeutics Inc
NTLA
Healthcare
Biotechnology
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including...
CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:NTLA)
New Post
View:
Posts & Comments
Threaded Posts
(10)
•••
MikeTester
X
Post by
MikeTester
on Aug 02, 2024 3:31am
Intellia Therapeutics, Inc. (NASDAQ:NTLA): Pioneering the Ne
https://beyondspx.com/2024/08/01/intellia-therapeutics-inc-nasdaqntla-pioneering-the-next-generation-of-gene-editing-therapies/
(10)
•••
lebaoxuiyo15
X
Post by
lebaoxuiyo15
on Nov 01, 2022 12:23pm
REVERSAL TIME
If youre a day trader, you should definitely check out BULLALERTS They send a watchlist covering the top pre-market movers every day before the open. Its a great way to pick out potential trades for
...more
(2)
•••
HarryPerkins
X
Post by
HarryPerkins
on Nov 18, 2021 9:09pm
🎥📰Anthony Durkacz on Building a Turnaround at FSD Pharma📣
(2)
•••
HarryPerkins
X
Post by
HarryPerkins
on Nov 17, 2021 9:57am
🎉📣FSD Pharma's Research and Clinical Advisory Board📢
Dr. Eleanor N. Fish, a world-renowned immunologist and cytokine expert, has been appointed to FSD Pharma's Research and Clinical Advisory Board. FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA
...more
(2)
•••
HarryPerkins
X
Post by
HarryPerkins
on Nov 10, 2021 2:03am
📣FSD Pharma:Agreement Signed With Covar Pharmaceuticals📢📣
(2)
•••
HarryPerkins
X
Post by
HarryPerkins
on Oct 30, 2021 10:17am
📢📣FSD Pharma forms agreement with Covar Pharmaceuticals 📢
(52)
•••
0checker
X
Post by
0checker
on Jun 29, 2021 5:53am
BORINGnews
https://ir.intelliatx.com/news-releases/news-release-details/intellia-and-regeneron-announce-landmark-clinical-data-showing
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Identifying new compelling targets on extensive and highly prospective land position
Developing a sizeable copper resource with a highly prospective exploration asset in Peru